JP2020500875A - 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 - Google Patents

統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 Download PDF

Info

Publication number
JP2020500875A
JP2020500875A JP2019529533A JP2019529533A JP2020500875A JP 2020500875 A JP2020500875 A JP 2020500875A JP 2019529533 A JP2019529533 A JP 2019529533A JP 2019529533 A JP2019529533 A JP 2019529533A JP 2020500875 A JP2020500875 A JP 2020500875A
Authority
JP
Japan
Prior art keywords
pyrido
hexahydro
isobutyl
dimethoxy
isoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019529533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500875A5 (enExample
JPWO2018102673A5 (enExample
Inventor
クリストファー エフ． オブライエン，
クリストファー エフ． オブライエン，
Original Assignee
ニューロクライン バイオサイエンシーズ，インコーポレイテッド
ニューロクライン バイオサイエンシーズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューロクライン バイオサイエンシーズ，インコーポレイテッド, ニューロクライン バイオサイエンシーズ，インコーポレイテッド filed Critical ニューロクライン バイオサイエンシーズ，インコーポレイテッド
Publication of JP2020500875A publication Critical patent/JP2020500875A/ja
Publication of JP2020500875A5 publication Critical patent/JP2020500875A5/ja
Publication of JPWO2018102673A5 publication Critical patent/JPWO2018102673A5/ja
Priority to JP2022189060A priority Critical patent/JP2023015405A/ja
Priority to JP2025010365A priority patent/JP2025071099A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019529533A 2016-12-02 2017-12-01 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 Withdrawn JP2020500875A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022189060A JP2023015405A (ja) 2016-12-02 2022-11-28 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
JP2025010365A JP2025071099A (ja) 2016-12-02 2025-01-24 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662429652P 2016-12-02 2016-12-02
US62/429,652 2016-12-02
PCT/US2017/064196 WO2018102673A1 (en) 2016-12-02 2017-12-01 Use of valbenazine for treating schizophrenia or schizoaffective disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022189060A Division JP2023015405A (ja) 2016-12-02 2022-11-28 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用

Publications (3)

Publication Number Publication Date
JP2020500875A true JP2020500875A (ja) 2020-01-16
JP2020500875A5 JP2020500875A5 (enExample) 2021-01-21
JPWO2018102673A5 JPWO2018102673A5 (enExample) 2022-04-08

Family

ID=60703209

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019529533A Withdrawn JP2020500875A (ja) 2016-12-02 2017-12-01 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
JP2022189060A Withdrawn JP2023015405A (ja) 2016-12-02 2022-11-28 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
JP2025010365A Pending JP2025071099A (ja) 2016-12-02 2025-01-24 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022189060A Withdrawn JP2023015405A (ja) 2016-12-02 2022-11-28 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
JP2025010365A Pending JP2025071099A (ja) 2016-12-02 2025-01-24 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用

Country Status (5)

Country Link
US (2) US20200078352A1 (enExample)
EP (2) EP3548027A1 (enExample)
JP (3) JP2020500875A (enExample)
TW (3) TW201827051A (enExample)
WO (1) WO2018102673A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3875459T (lt) 2015-10-30 2024-02-26 Neurocrine Biosciences, Inc. Valbenazino dihidrochlorido druskos ir jų polimorfai
CA3009169A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
JP7090151B2 (ja) 2017-01-27 2022-06-23 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
MA50175B1 (fr) 2017-09-21 2025-05-30 Neurocrine Biosciences, Inc. Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors
CA3086611C (en) 2017-12-26 2023-07-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
WO2019241555A1 (en) 2018-06-14 2019-12-19 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
CN110818705A (zh) * 2018-08-14 2020-02-21 苏州鹏旭医药科技有限公司 缬苯那嗪的盐型和相应晶型与其制备方法
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN112933055B (zh) * 2021-03-23 2023-01-13 安徽九华华源药业有限公司 帕利哌酮胃滞留片及其制备方法
JP2024524324A (ja) * 2021-06-30 2024-07-05 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症のアドオン処置において使用するためのバルベナジン
US20250064990A1 (en) 2021-08-20 2025-02-27 Neurocrine Biosciences, Inc. Methods of screening for vmat2 inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504622A (ja) * 2005-08-06 2009-02-05 ケンブリッジ、ラボラトリーズ、（アイルランド）、リミテッド 医薬化合物
JP2012515720A (ja) * 2009-01-20 2012-07-12 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体
JP2013531075A (ja) * 2010-04-08 2013-08-01 エスピーエフ ロジカ エス．アール．エル． 任意表面への電気回路の製作手順
WO2015085004A1 (en) * 2013-12-03 2015-06-11 Intra-Cellular Therapies, Inc. Novel methods
WO2015120317A1 (en) * 2014-02-07 2015-08-13 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
WO2015171802A1 (en) * 2014-05-06 2015-11-12 Neurocrine Biosciences, Inc. Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
US20170145008A1 (en) * 2015-10-30 2017-05-25 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
US6139865A (en) 1996-10-01 2000-10-31 Eurand America, Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DK0946169T3 (da) 1996-12-20 2003-04-22 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af et præparat med vedvarende frigivelse
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
EP1313473A2 (en) 2000-08-30 2003-05-28 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
AU2007317242B2 (en) 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
EP3345905B1 (en) 2008-09-18 2021-09-01 Auspex Pharmaceuticals, Inc. Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
CA2771539A1 (en) 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
CN113713108A (zh) * 2015-06-23 2021-11-30 纽罗克里生物科学有限公司 用于治疗神经学疾病或病症的vmat2抑制剂

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504622A (ja) * 2005-08-06 2009-02-05 ケンブリッジ、ラボラトリーズ、（アイルランド）、リミテッド 医薬化合物
JP2012515720A (ja) * 2009-01-20 2012-07-12 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体
JP2013531075A (ja) * 2010-04-08 2013-08-01 エスピーエフ ロジカ エス．アール．エル． 任意表面への電気回路の製作手順
WO2015085004A1 (en) * 2013-12-03 2015-06-11 Intra-Cellular Therapies, Inc. Novel methods
WO2015120317A1 (en) * 2014-02-07 2015-08-13 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
WO2015171802A1 (en) * 2014-05-06 2015-11-12 Neurocrine Biosciences, Inc. Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
US20170145008A1 (en) * 2015-10-30 2017-05-25 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskine", NEUROCRINE BIOSCIENCES : INVESTORS : PRESS RELEASE, JPN7021003897, 2013, pages 1 - 7, ISSN: 0004599851 *

Also Published As

Publication number Publication date
WO2018102673A1 (en) 2018-06-07
EP4400171A3 (en) 2024-09-11
JP2023015405A (ja) 2023-01-31
TW202345829A (zh) 2023-12-01
TW202515564A (zh) 2025-04-16
EP4400171A2 (en) 2024-07-17
US20210113553A1 (en) 2021-04-22
JP2025071099A (ja) 2025-05-02
TW201827051A (zh) 2018-08-01
EP3548027A1 (en) 2019-10-09
US20200078352A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
JP2025071099A (ja) 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
US10851104B2 (en) Valbenazine salts and polymorphs thereof
EP3313402B1 (en) Vmat2 inhibitors for treating neurological diseases or disorders
WO2018200605A1 (en) Use of valbenazine for treating levodopa-induced dyskinesia
EP3612532B1 (en) Vmat2 inhibitor compounds and compositions thereof
WO2018164996A1 (en) Dosing regimen for valbenazine
AU2017356926A1 (en) Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
HK40109084A (en) Valbenazine salts and polymorphs thereof
HK40051183B (en) Valbenazine dihydrochloride salts and polymorphs thereof
HK40051183A (en) Valbenazine dihydrochloride salts and polymorphs thereof
HK1248116B (en) Vmat2 inhibitors for treating neurological diseases or disorders
EA043769B1 (ru) Соли валбеназина и их полиморфы
BR112018008460B1 (pt) Formas cristalinas e amorfas de valbenazina, suas misturas, seus usos e seus processos de preparação, e composição farmacêutica
HK1260336B (en) Valbenazine ditosylate and polymorphs thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210520

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220224

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220328

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221128

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221128

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221206

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221207

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20221208